LeioMyoSarcoma Direct Research Foundation - LMSdr

Home Patient Registries The Foundation eAlerts What is Leiomyosarcoma? News and Advocacy How to Help Donate Now Memorials and Tribute Funds Thank you, Donors Fundraisers Patient Resources Clinical Trials Tissue Bank Research Grants Contact Us

LMSarcoma Direct Research urges you to join our special fundraising campaign to support Dr. van de Rijn’s research CD47 & LMS.


CD47 & LMS
Research Fund

[When donating through Paypal,
please indicate CD47 in the 'Designation or Comments' section.
When donating by check,
please indicate CD47 in the memo section.]

WHY? A study conducted by Dr. Matt van de Rijn demonstrated dramatic results using CD47 on mice with metastatic LMS tumors.

Antibody Therapy Targeting the CD47 Protein is Effective in a Model of Aggressive Metastatic Leiomyosarcoma PNAS April 24, 2012 vol. 109 no. 17

Flipping the Script on Macrophages in Leiomyosarcoma
OncoImmunology 1:8, 1-3; November 2012; © 2012 Landes Bioscience

A second but different study of CD47 and LMS would help promote human clinical trials for LMS patients, and might even be more effective.

Our goal is to raise $50,000 by October 1st, 2013 so that Dr. Matt van de Rijn could begin this work as soon as possible.

For every dollar raised, LMSarcoma Direct Research will match the same amount. Ask your employer, friends and family to do the same with you!

Slides of mice LMS lung metastasis before and after treatment with CD47

This image came from: PMID: 22451919. Proceedings of the National Academy of Sciences. 109: 6656-61

More LMS research by Dr. Matt van de Rijn:

Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling Oncogene (2010) 29 http://www.ncbi.nlm.nih.gov/pubmed/19901961


Using immunohistochemistry and genetic analysis the lab was able to identify subgroups of Leiomyosarcoma. They found that all LMS patients fall into one of three subgroups: group 1 being muscle-enriched sarcomas, and with groups 2 & 3 not being as distinct or differentiated. Patients falling into group 1 had statistically better outcomes while patient tumors presenting with a CSF1 cytokine (cell signaling protein) correlated with a negative patient outcome.

CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis. The American Journal of Pathology Vol. 179, No.4 in October 2011


This paper is very closely related to the “Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling” paper, which correlated the presence of CSF1 cytokines (cell signaling protein) in LMS tumors with poor patient outcome. CSF1 causes tumor-associated macrophages to multiply rapidly. Tumor associated macrophages increase tumor blood vessel development, which in turn causes tumors to go from dormant to malignant. Patterns of CSF1 expression and subsequent tumor associated macrophage recruitment is found to be consistent between both patient’s primary tumors as well as their metastases.

Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma
Sarcoma Volume 2012, Article ID 805614, 9 pagesdoi:10.1155/2012/805614

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour J Pathol 2012; 227: 223–233

Back to Top

Last Edited - 12 April 2013 01:30 am